Cargando…
Immune checkpoints in thymic epithelial tumors: challenges and opportunities
Thymic malignancies are rare mediastinal cancers, classified according to the World Health Organization's histopathologic classification which distinguishes thymomas from thymic carcinomas. One key consideration when discussing immunotherapy for thymic epithelial tumors is that one-third of pat...
Autor principal: | Girard, Nicolas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9216246/ https://www.ncbi.nlm.nih.gov/pubmed/35757304 http://dx.doi.org/10.1016/j.iotech.2019.09.002 |
Ejemplares similares
-
Immunobiology of Thymic Epithelial Tumors: Implications for Immunotherapy with Immune Checkpoint Inhibitors
por: Tateo, Valentina, et al.
Publicado: (2020) -
Immune checkpoint inhibitors for treatment of thymic epithelial tumors: how to maximize benefit and optimize risk?
por: Zhao, Chen, et al.
Publicado: (2019) -
Emerging biomarkers for checkpoint inhibitors in thymic epithelial tumors
por: Owen, Dwight H., et al.
Publicado: (2019) -
Perspective of Immune Checkpoint Inhibitors in Thymic Carcinoma
por: Kaira, Kyoichi, et al.
Publicado: (2021) -
Epigenetics of Thymic Epithelial Tumors
por: Nicolì, Vanessa, et al.
Publicado: (2023)